by Colin Kenny, GP, Dromore
In DCCT (the Diabetes Control and Complications Trial), 1441 participants with type 1 diabetes were randomly assigned to receive either intensive treatment or conventional treatment. At the end of the trial all participants were instructed in intensive treatment and invited to join the observational EDIC (Epidemiology of Diabetes Interventions and Complications) study.
After 18 years of follow-up, the prevalence of new cases of microalbuminuria was significantly less in the group who had received intensive treatment during DCCT compared with the group receiving conventional treatment during DCCT. The investigators concluded that in individuals with type 1 diabetes, intensive diabetes treatment gave durable renal benefits that persist for at least 18 years.
To access the full publication, click here (log-in or purchase required)
